ClinicalTrialsFinder

Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound Clinical Trials in Milan

1 recruitingMilan, Italy

Showing 1–1 of 1 trials

Recruiting
Phase 2

Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure

Unresectable or Metastatic Hepatocellular CarcinomaChild-Pugh A Hepatocellular CarcinomaFailure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound
CatalYm GmbH104 enrolled2 locationsNCT07219459